Aidi injection plus platinum-based chemotherapy for stage IIIB/IV non-small cell lung cancer: A meta-analysis of 42 RCTs following the PRISMA guidelines
- PMID: 29655852
- DOI: 10.1016/j.jep.2018.04.013
Aidi injection plus platinum-based chemotherapy for stage IIIB/IV non-small cell lung cancer: A meta-analysis of 42 RCTs following the PRISMA guidelines
Abstract
Ethnopharmacological relevance: Aidi injection is one of the most commonly used Chinese patent medicines for advanced non-small cell lung cancer (NSCLC). It is made from an extraction of Mylabris Phalerata, Radix Astragalus, Radix Ginseng, and Acanthopanax Senticosus.
Aim of the study: The objective of this study is to evaluate the efficacy and safety of Aidi injection in combination with platinum-based chemotherapy for stage IIIB/IV NSCLC.
Materials and methods: A systematic review and meta-analysis were performed following the PRISMA (the Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Trials were combined using Review Manager 5.3 and Comprehensive Meta-Analysis(CMA) 2.0. Dichotomous data were expressed as risk ratio (RR) and continuous outcomes as weighted mean difference (WMD), with their 95% confidence intervals (CI) respectively. All randomized controlled trials (RCTs) comparing Aidi injection plus platinum-based chemotherapy versus platinum-based chemotherapy, with efficacy and safety outcomes were selected. Disease Control Rate (DCR) was the primary outcome, Objective Response Rate (ORR), survival rate, quality of life (QOL), and toxic effects were the secondary outcomes.
Results: 42 RCTs recruiting 4081 patients with stage IIIB/IV NSCLC were included, with overall low-moderate methodological quality. Compared with platinum-based chemotherapy alone, Aidi injection plus platinum-based chemotherapy can increase relative benefit of DCR (RR = 1.13, 95% CI 1.09-1.16, P < 0.00001), ORR (RR = 1.26, 95% CI 1.18-1.36, P < 0.00001), improve 1-, 2-, 3-year survival rates (RR = 1.14, 95% CI 1.02-1.28, P = 0.03; RR = 1.31, 95% CI 1.05-1.64, P = 0.02; and RR = 1.88, 95% CI 1.32-2.67, P = 0.0005, respectively), QOL (RR = 1.80, 95% CI 1.61-2.01, P < 0.00001), and reduce severe (grade 3 and 4) toxicities by 36% (RR = 0.64, 95% CI 0.58-0.70, P < 0.00001).
Conclusions: From the available evidence, compared with platinum-based chemotherapy alone, Aidi injection plus platinum-based chemotherapy improves the clinical efficacy and alleviates the toxicity of chemotherapy in patients with stage IIIB/IV NSCLC. However, considering the intrinsic limitations of the included RCTs, well-designed, rigorously performed, high-quality trials are still required to further assess and confirm the results.
Keywords: Aidi injection; Astragaloside II (PubChem CID: 71306915); Astragaloside IV (PubChem CID: 13943297); Cantharidin (PubChem CID: 5944); Chemotherapy; Efficacy; Ginsenoside Rb1 (PubChem CID: 118987129); Ginsenoside Rc (PubChem CID: 12855889); Ginsenoside Rd (PubChem CID: 24721561); Ginsenoside Re (PubChem CID: 441921); Ginsenoside Rg1 (PubChem CID: 441923); Ginsenoside Rg3 (PubChem CID: 9918693); Ginsenoside Rh2 (PubChem CID: 119307); Isofraxidin (PubChem CID: 5318565); Meta-analysis; NSCLC; Safety; Stage IIIB/IV; Syringin (PubChem CID: 5316860); Systematic review; Toxicity; Trial Sequential Analysis.
Copyright © 2018 Elsevier B.V. All rights reserved.
Similar articles
-
Clinical efficacy and safety of Aidi injection plus paclitaxel-based chemotherapy for advanced non-small cell lung cancer: A meta-analysis of 31 randomized controlled trials following the PRISMA guidelines.J Ethnopharmacol. 2019 Jan 10;228:110-122. doi: 10.1016/j.jep.2018.09.024. Epub 2018 Sep 20. J Ethnopharmacol. 2019. PMID: 30243827
-
Chinese patent medicine Aidi injection for cancer care: An overview of systematic reviews and meta-analyses.J Ethnopharmacol. 2022 Jan 10;282:114656. doi: 10.1016/j.jep.2021.114656. Epub 2021 Sep 20. J Ethnopharmacol. 2022. PMID: 34551361 Review.
-
Can Aidi injection improve overall survival in patients with non-small cell lung cancer? A systematic review and meta-analysis of 25 randomized controlled trials.Complement Ther Med. 2018 Apr;37:50-60. doi: 10.1016/j.ctim.2018.01.011. Epub 2018 Jan 31. Complement Ther Med. 2018. PMID: 29609937
-
Shenqi fuzheng, an injection concocted from Chinese medicinal herbs, combined with platinum-based chemotherapy for advanced non-small cell lung cancer: a systematic review.J Exp Clin Cancer Res. 2010 Oct 22;29(1):137. doi: 10.1186/1756-9966-29-137. J Exp Clin Cancer Res. 2010. PMID: 20969765 Free PMC article.
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320. Health Technol Assess. 2001. PMID: 12065068
Cited by
-
Therapeutic Potential of Ginsenosides in Anthracycline-Induced Cardiotoxicity.Molecules. 2025 Jun 10;30(12):2527. doi: 10.3390/molecules30122527. Molecules. 2025. PMID: 40572494 Free PMC article. Review.
-
Comparative efficacy of various CHIs combined with western medicine for non-small cell lung cancer: A bayesian network meta-analysis of randomized controlled trials.Front Pharmacol. 2022 Nov 10;13:1037620. doi: 10.3389/fphar.2022.1037620. eCollection 2022. Front Pharmacol. 2022. PMID: 36438813 Free PMC article.
-
Medicinal Plants and Mushrooms with Immunomodulatory and Anticancer Properties-A Review on Hong Kong's Experience.Molecules. 2021 Apr 9;26(8):2173. doi: 10.3390/molecules26082173. Molecules. 2021. PMID: 33918834 Free PMC article. Review.
-
Meta-Analysis of Aidi Injection and First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy in Treating Advanced Non-Small Cell Lung Cancer.J Evid Based Integr Med. 2021 Jan-Dec;26:2515690X211010733. doi: 10.1177/2515690X211010733. J Evid Based Integr Med. 2021. PMID: 33926244 Free PMC article.
-
SphK1 functions downstream of IGF-1 to modulate IGF-1-induced EMT, migration and paclitaxel resistance of A549 cells: A preliminary in vitro study.J Cancer. 2019 Jul 10;10(18):4264-4269. doi: 10.7150/jca.32646. eCollection 2019. J Cancer. 2019. PMID: 31413745 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous